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MOBILIZATIONWITH CHEMOTHERAPY COMPARED TO G-CSF ALONE: AN
ANALYSIS OF RESOURCE USE AND COST IN AUTOLOGOUS STEM CELL
TRANSPLANT PATIENTS
Pelletier, E.M.1, Smith, P.J.1, Dembek, C.J.2 1 IMS Consulting, Water-
town, MA; 2Genzyme Corporation, Cambridge, MA
Objectives: The most common mobilization regimens for autol-
ogous stem cell transplant (ASCT) are granulocyte-colony stimulat-
ing factor (G-CSF) alone or in combination with chemotherapy.
Chemotherapy plus G-CSF has been shown to mobilize more cells
than G-CSF alone but often at the expense of costly side effects.
The purpose of this study was to evaluate resource use and cost
during mobilization for patients mobilized with chemotherapy plus
G-CSF vs. G-CSF alone.
Methods: Patients 18 years of age or older with evidence of ASCT
between January 1, 2000 and December 31, 2006 were identified
from a nationally-representative database of private payer medical
and pharmacy claims. Patients had to receive apheresis within 60
days prior to ASCT and have a history of multiple myeloma, non-
Hodgkin’s lymphoma, or Hodgkin’s disease; patients also were
required to be continuously enrolled in one health plan for at least
90 days pre-ASCT and have no evidence of a prior ASCT. Using
claims data, patients were classified into one of two mobilization
regimens: G-CSF alone or chemotherapy with G-CSF. Total
resource use and direct medical costs were calculated from the
time of administration of themobilization regimen to the first apher-
esis day; paid claims were used as a proxy for costs and expressed in
2006 US$.
Results: 235 ASCT patients were identified; 172 (73%) were
mobilized with G-CSF alone and 63 (27%) with chemotherapy
and G-CSF. Total mobilization costs were 27% higher among
patients mobilized with chemotherapy versus those mobilized
with G-CSF alone ($39,686 vs. $31,251, P 5 0.020). Patients
mobilized with chemotherapy had higher inpatient hospital costs
($8,225 vs. $5,854, P 5 0.056), more use of growth factor
($9,217 vs. $6,948, P 5 0.003), and higher pharmacy costs
($5,343 vs. $1,484, P\0.001) than patients mobilized with G-
CSF alone. Rituximab comprised 48% of pharmacy costs in
the chemotherapy and G-CSF group, while the remaining costs
were due to chemotherapy drugs, MESNA, and anti-emetics. Ex-
cluding rituximab and G-CSF, patients mobilized with chemo-
therapy had pharmacy costs that were $1,645 higher than
patients mobilized with G-CSF alone.
Conclusion: ASCT patients mobilized with chemotherapy had
higher total mobilization costs than patients mobilized with G-
CSF alone. This significant difference in costs was due tomore costly
hospitalizations and greater use of G-CSF and other pharmaceuti-
cals in patients mobilized with chemotherapy.Total Mobilization Costs for Chemotherapy and G-CSF vs.
G-CSF Alone
Chemotherapy
and G-CSF G-CSF AloneMean (SD) Mean (SD) % Difference P-valueTotal
Mobilization
Costs$39,686 (31,188) $31,251 (31,750) 27% 0.020Inpatient $8,225 (19,214) $5,854 (18,312) 41% 0.056
Outpatient $16,901 (17,085) $16,965 (19,772) 0% 0.971
Pharmacy $14,560 (12,067) $8,432 (13,502) 73% \0.001
- G-CSF $9,217 (7,069) $6,948 (10,514) 33% 0.003
- Rituximab $2,547 (6,228) $332 (1,625) 667% \0.001
- Other retail
pharmacy
$2,797 (2,923) $1,152 (2,644) 143% \0.00193
CD341 CELL YIELD ON DAY 1 OF APHERESIS PREDICTS TOTAL CD341
CELL MOBILIZATION, NEUTROPHIL RECOVERY, AND SURVIVAL AFTER
AUTOLOGOUS STEM CELL TRANSPLANTATION FOR LYMPHOMA
Dean, R.1, Rybicki, L.2, Pohlman, B.1, Sweetenham, J.1, Sobecks, R.1,
Copelan, E.1, Kalaycio, M.1, Smith, S.1, Andresen, S.1, Bolwell, B.1
1Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; 2Cleveland
Clinic Taussig Cancer Institute, Cleveland, OH
Lymphoma patients who mobilize CD341 cells poorly have infe-
rior outcomes after autologous stem cell transplantation (ASCT).
Identifying poor mobilizers early may allow intervention (e.g., add-
ing plerixafor) to improve mobilization. We retrospectively com-
pared CD341 cell yields on day 1 (D1) of autologous stem cell
collection with the total CD341 cell yield and with ASCT outcomes
including neutrophil (ANC) recovery .500 cells/ul, nonrelapse
mortality (NRM), relapse-free survival (RFS), and overall survival
(OS). Patients (n 5 411) underwent ASCT at a single center from
1998 through 2007. Diagnoses were Hodgkin lymphoma (n 5 83),
aggressive B-cell NHL (n 5 196), indolent B-cell NHL (n 5 64),
mantle cell NHL (n5 37), or T-cell NHL (n5 31). All were mobi-
lized with etoposide 2 g/m2 and filgrastim 10 ug/kg. After WBC re-
covery to 1000/uL, leukapheresis commenced for$2 days and up to
5 days, to a target dose of $7 (minimum $2) million CD341 cells/
kg. Conditioning for ASCT was high-dose busulfan, cyclophospha-
mide, and etoposide. Median follow-up among 248 survivors is 42
months. Causes of death were relapse (66%), NRM (28%) and un-
known (6%). Total CD341 cell yield was median 8.82 million/kg
(range, 2 to 162) in 3 days of apheresis (range, 2 to 20). Median
D1 yield was 1.98 million CD341 cells/kg (range, 0 to 120). The
D1 yield was strongly correlated with total CD341 cell yield (R 5
0.87, P\0.001) and days of apheresis required (R 520.87,
P\0.001). Higher D1 yield (by patient quintiles) was associated in
univariable analyses with faster ANC recovery after ASCT
(P\0.001), lower NRM (P 5 0.03), better OS (P 5 0.03, P 5
0.001, and P\0.01 for quintiles 3, 4, and 5 vs. quintile 1), and better
RFS (P\0.01 and P 5 0.04 for quintiles 4 and 5). In multivariable
analyses, D1 yield and Karnofsky performance status (KPS) were
prognostic for NRM; D1 yield, KPS, lymphoma histology, number
of prior chemotherapy regimens, and pre-ASCT disease status were
prognostic for RFS; and D1 yield, age, KPS, histology, number of
prior regimens, and number of days of apheresis were prognostic
for OS. These data extend our prior observation that stem cell mo-
bilization is associated with ASCT outcomes in lymphoma patients.
TheD1 CD341 cell yield predicts the total CD341 cell yield, ANC
recovery after ASCT, NRM, and survival. Poor mobilizers are iden-
tifiable on D1 of CD341 cell collection and represent a patient sub-
group in which to test interventions to improve mobilization and
potentially other ASCT outcomes.94
DAY 15 INTERLEUKIN 15 LEVELS AFFECT NATURAL KILLER CELL RE-
COVERY AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION
Porrata, L.F., Inwards, D.J., Micallef, I.N., Johnston, P.B., Ansell, S.M.,
Markovic, S.N. Mayo Clinic, Rochester, MN
Recently, we reported in a prospective study (Porrata et al. Biology
of Blood&MarrowTransplantation 2008;14(7):807–16) that the ab-
solute number of natural killer (NK) cells at day 15 post-autologous
stem cell transplantation (ASCT) affects survival. Factors affecting
NK cell recovery at day 15 post-ASCT are not completely under-
stood. Interleukin-15 (IL-15) is a cytokine associated with NK cell
differentiation and homeostasis. Thus, we studied the role of day
15 IL-15 on NK cell recovery post-ASCT. From February 2002 to
February 2007, 50non-Hodgkin lymphoma (NHL)patients enrolled
in the study. We identified higher levels of day 15 IL-15 compared
with normal controls and pre-ASCT IL-15 levels [normal IL-15
levels: median 5 0 pg/ml (range: 0–3.37 pg/ml); pre-ASCT IL-15
levels: median 5 0.09 pg/ml (range: 0–229.42 pg/ml); and day 15
IL-15: median 5 5.48 pg/ml (range: 0–36.94), p\ 0.0001)]. ROC
curve and AUC analysis showed that day 15 IL-15 was a significant
marker forNKcell recovery (AUC5 0.87, p\0.0001).The best cut-
off level was 9.5 pg/ml. Groups (#9.5 or.9.5 pg/ml) were balanced
in regard to histology (p 5 0.48); gender (p 5 0.8); stage (p 5 0.7);
LDH (p5 0.5); disease status prior to ASCT (p5 0.9); performance
Poster Session-I 39status (P5 0.1); and extra nodal involvement (p5 0.4).We identified
an inverse correlation between day 15 IL-15 and day 15 NK cell re-
covery (r 5 20.5, p\ 0.0001). Patients with a day15 IL-15 # 9.5
pg/ml experienced higher numbers of NK cells compared with those
with a day 15 IL-15. 9.5 pg/ml [median 142 cells/ml (range: 10–416
cells/ml) versus median 57.5 cells/ml (range: 28–999 cells/ml), p\
0.001, respectively]. Using logistic regression models, univariately
day 15 IL-15 was a predictor for NK cell recovery (p\0.0003) and
multivariately day 15 IL-15 remained a predictor for NK cell recov-
ery (p\0.0004). To our knowledge, this is the first study showing an
associationbetweenday 15 IL-15 andNKcell recovery inASCT.We
showed an inverse relationship between day 15 IL-15 and NK cell
numbers consistent with a homeostatic association. The data pre-
sented here suggest that day 15 NK cell recovery might be driven
by the cytokine milieu post-ASCT.95
IMMUNOTHERAPY WITH RITUXIMAB (RITUXAN)/INTERLEUKIN 2 (IL-2)
FOLLOWING AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANS-
PLANT (ASCT) AS TREATMENT FOR CD20 POSITIVE NON-HODGKIN’S
LYMPHOMA
Holmberg, L.A.1,2,3, Maloney, D.G.1,2,3, Bensinger, W.I.1,2,3 1Fred
Hutchinson Cancer Research Center (FHCRC), Seattle, WA; 2University
of Washington School of Medicine, Seattle, WA; 3Puget Sound Oncology
Consortium, Seattle, WA
Relapse of NHL is a problem after ASCT. Early after ASCT, the
immune system is not as active, which can impair the ability to erad-
icate residual disease. The addition of immunotherapy may decrease
the incidence of relapse and prolong survival. In a phase I/II trial at
FHCRC, the immune-modulator IL-2 increased NK and LAK ac-
tivity in vitro. Since Rituxan lyses CD201 cells by ADCC, adding
Rituxan to IL-2 should boost its effectiveness. Twenty patients
with CD201NHL received ASCT followed by Rituxan/IL-2 ther-
apy. The pathology at ASCT included: follicular small/large cleaved
(n5 2), diffuse large/T cell rich B cell (n5 8), mantle cell (n5 4) and
transformed from indolent to diffuse (n 5 6). The disease status at
ASCT was refractory (n 5 8), relapse 1 (PR) (n 5 1), remission 1
(n 5 3), remission 2 (n5 6) and relapse/untreated (n 5 1). Previous
Rituxan use was (n 5 9). The median age of patients was 46 years
(range 31–70). The median time to initiation of therapy was 79
days post ASCT (range 49–100). The treatment schema was: IL-2
0.6  106 IU/m2/day sc times 12 weeks, followed by 1.4  106 IU/
m2 sc 3 times/week for an additional 12 weeks (total of 24 weeks of
IL-2 therapy). Rituxan was given iv at 375 mg/m2 for a total of 4
doses: beginning one day prior to starting IL-2, then between days
25–30, 50–55 and 75–80 post beginning IL-2. NCI Common Tox-
icity Criteria were used to evaluate adverse events. Most common
grade 3/4 toxicities were neutropenia (n 5 9), pneumonia (n 5 2)
at 7–8 weeks of therapy, hypothyroidism (n 5 1), hypokalemia
(n 5 1) and pulmonary dysfunction (decreased DLCO) (n 5 1) at
5 weeks of therapy. Neutropenia responded to G-CSF. There
were 11 infections: pneumonia (influenza, n5 1, and pneumococcus
strept, n 5 1), oral thrush (n 5 2), herpes simplex (n 5 1), urinary
tract (n5 1), zoster (n5 1) and upper respiratory (n5 4).Most com-
mon side effects were fatigue, erythema/induration/discomfort at
IL-2 injection sites and flu-like symptoms. Seven patients stopped
therapy due to subdural hematoma/progression of NHL (n 5 1),
pneumonia (n 5 2), decreased DLCO (n 5 1) or at own/physician’s
choice without grade 3/4 toxicity at 9, 13, 14.5 weeks after complet-
ing Rituxan (n5 3). With a median follow-up of 76.5 months (range
43–93), 18 patients (90%) are alive, 17 patients (85%) are alive inCR.
Two patients died of relapsed disease. The combination of IL-2/Rit-
uxan after ASCT continues to show a high and durable response rate
in CD201 NHL patients.96
AUTOLOGOUS HEMATOPOEITIC STEM CELL TRANSPLANTATION (HSCT)
IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) IN FIRST OR SEC-
OND REMISSION
Naqvi, H., John, V., Devoe, C., Kiner, B., Kolitz, J., Allen, S.,
Gissinger, D., Cannon, M., Fitzgerald, E., Klocke, J., Bayer, R.-L. North
Shore University Hospital, Manhasset, NYWe report 40 patients (pts) with AMLwho underwent autologous
HSCT in first (CR1) or second (CR2) remission from 2002 to 2007.
Twenty one were male and nineteen were female with a mean age of
52.8 (range 35–66) years. Patients enrolled in clinical trials are not
included in this analysis. Using CALGB (Byrd) criteria, 6 had favor-
able cytogenetic risk (all in CR2), 26 had intermediate risk, including
22 with normal karyotypes (20 in CR1 and 2 in CR2), and 8 had un-
favorable cytogenetics (7 in CR1 and 1 in CR2), including two pa-
tients with t(9;22). One pt had Ph1 AML and one CML with
myeloid blast crisis. One patient had AML transformed frommyelo-
dysplastic syndrome (MDS). Four patients had AMLwith multi-lin-
eage dysplasia (MLD). Nine patients were in CR2. Thirty-five
patients had intensification / mobilization with high dose VP16/
ARAC, four with high dose ARAC and one patient had a bone mar-
row harvest. Thirty-six patients received Busulfan (0.8mg/kg x 16
doses) and VP-16 (60mg/kg) as their preparative regimen. Four re-
ceived Busulfan (0.8 mg/kg x 16 doses) and Cytoxan (120 mg/kg).
One hundred day transplant related mortality was 2.5%.Mean over-
all survival was 20.9 months. Mean disease free survival was 36.7
months with a range of 10–76 months. One year overall survival
was 63%, with a one year disease free survival of 40%. Four of six
pts with favorable cytogenetics are alive in CR more than 24 months
after autologous transplant. Two patients with t(9;22) are on imati-
nib maintenance in CR 12 and 42 months post transplant. One pa-
tient with APL developed a secondary MDS with a monosomy 7.
No patients with prior MDS or MLD were alive after 12 months.
Five patients who relapsed after autologous HSCT went on to re-
ceive reduced intensity allogeneic transplantation with a 100 day
mortality of 0%. We conclude that autologous HSCT should be
considered an effective and safe post-remission consolidation ther-
apy for pts with intermediate risk AML in CR1 and for pts with fa-
vorable cytogenetics in CR2. Patients with MLD and prior MDS
do poorly. Prior autologous HSCT does not increase the 100 day
mortality with reduced intensity allogeneic transplantation. Further
studies are necessary, continuing to focus on risk-adapted therapy
and assessing quality of life endpoints.97
PHYSICAL PERFORMANCE FACTORS AND OVERALL SURVIVAL AFTER AU-
TOLOGOUS AND ALLOGENEIC BMT
Hahn, T.1, Smiley, S.L.1, Tan, W.2, Wilding, G.2, Thomas, J.1,
Fassl, K.1, Wright, C.1, Battiwalla, M.1, McCarthy, P.L.1 1Roswell
Park Cancer Institute, Buffalo, NY; 2Roswell Park Cancer Institute, Buf-
falo, NY
Many tests are used to determine patient physical fitness for
blood and marrow transplant (BMT). BMT patients usually re-
ceive prior toxic therapies that result in deconditioning pre-
BMT. One measure of physical fitness is the ability to reach
a target heart rate without a significant decrease in oxygen satu-
ration (O2sat) during exercise. We retrospectively analyzed 183
consecutive first adult ($18 years) autologous (n 5 95) or alloge-
neic (n 5 88) BMT pts treated from 7/05 to 4/08 to analyze
overall survival (OS) in relation to a pre-BMT physical therapy
evaluation, along with standard cardiac and pulmonary function
tests. The physical therapy evaluation included Karnofsky perfor-
mance score (KPS), resting and post-exercise heart rate (HR) and
O2sat, ability to reach target HR and ability to complete an ex-
ercise test consisting of 50 step-ups or walking on a treadmill.
Median age was 53 yrs (range 18–71), male 61%, White 93%,
leukemia (n 5 65), lymphoma (n 5 68), myeloma (n 5 24), he-
matologic disorders (n 5 23), and solid tumors (n 5 3), donors
were autologous (n 5 95), related (n 5 37), or unrelated (n 5
51). Median follow-up in survivors was 1 yr (range 0.1–2.9).
162 (89%) were able to complete the exercise test; reasons for
not completing the test included fatigue and rapid heart rate.
37% of autologous and 21% of allogeneic BMT patients who
completed the exercise test reached their target HR. Medians
(ranges) were: resting HR 87.5 (56–150) and O2sat 98 (89–
100), post-exercise HR 126.5 (72–186) and O2sat 98 (88–100),
left ventricular ejection fraction (LVEF) 61 (50–80), corrected
carbon monoxide diffusing capacity (DLCOcorr) 80 (35–126),
forced expiratory volume in one second (FEV1) 95 (35–146).
Multivariate analysis used a Cox proportional hazards model
with backward elimination with the following potential
